Document is current
Any future updates will be listed below
-
Authors
Urpa, Lea https://orcid.org/0000-0002-8712-3518
Kurki, Mitja I.
Rahikkala, Elisa https://orcid.org/0000-0003-2760-7059
Hämäläinen, Eija
Salomaa, Veikko https://orcid.org/0000-0001-7563-5324
Suvisaari, Jaana https://orcid.org/0000-0001-7167-0990
Keski-Filppula, Riikka
Rauhala, Merja
Korpi-Heikkilä, Satu
Komulainen-Ebrahim, Jonna
Helander, Heli
Vieira, Päivi https://orcid.org/0000-0002-0796-8706
Uusimaa, Johanna
Moilanen, Jukka S. https://orcid.org/0000-0002-8041-3205
Körkkö, Jarmo
Singh, Tarjinder https://orcid.org/0000-0003-0601-6815
Kuismin, Outi
Pietiläinen, Olli https://orcid.org/0000-0003-4387-1861
Palotie, Aarno https://orcid.org/0000-0002-2527-5874
Daly, Mark J.
- License Information
-
More Information
Article History
Received: 11 July 2023
Revised: 19 January 2024
Accepted: 22 February 2024
First Online: 11 March 2024
Ethical approval
: Ethical permission for the Northern Finnish Intellectual Disability study protocol has been given by the Joint Authority for the Hospital District of Northern Ostrobothnia, Regional Ethics Committee (latest decision on November 2015, §340) in accordance with the Finnish Medical Research Act (488/1999). All subjects and/or their legal guardians provided written informed consent to participate in the study.
: AP is the chief scientific officer for the FinnGen project that is co-funded by 13 international pharmaceutical companies. VS. has had research collaboration with Bayer Ltd (unrelated to the present study).
